Neuphoria Therapeutics Beat Consensus Estimates

Neuphoria Therapeutics (NEUP) reported a loss of $0.09 per share on revenue of $0.00 million for the fiscal third quarter ended March 2026. The consensus estimate was a loss of $0.56 per share. The company beat consensus estimates by 83.93% while revenue fell 100.00% compared to the same quarter a year ago.

Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.